Wednesday, May 27, 2020 Presentation time: 12:05 p.m. ET Company Attendee: CEO Richard Chin Webcast URL: Click here For more information about this event, please see the press release.
San Francisco, California (May 13, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2020 Virtual Jaws & Paws Conference on May 27. Dr. Richard Chin, Chief Executive Officer, will present via webcast at 12.05pm ET and be available for virtual one-on-one […]
San Francisco, California (May 7, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2020 and provided updates on its programs. For the first quarter 2020, KindredBio reported net product revenues of $0.6 million […]
Thursday, May 7, 2020 Time of Event: 4:30 p.m. Eastern time/1:30 p.m. Pacific time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID: 4476025 For more information about this event, please see the press release.
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Thursday, May 7, 2020. San Francisco, California (April 23, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2020 financial results on May 7, […]
San Francisco, California (April 15, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has completed the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million, and royalties on worldwide sales. “We are pleased […]
San Francisco, California (March 24, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of atopic dermatitis in dogs. The […]
San Francisco, California (March 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million and royalties on worldwide […]
Monday, March 16, 2020 Time of Event: 4:30 p.m. Eastern time/1:30 p.m. Pacific time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID: 2367136 For more information about this event, please see the press release.
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, March 16, 2020. San Francisco, California (March 3, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth quarter and year-end 2019 financial results […]
-0.02 (-0.45%)
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
